New data reported this week suggest that GLP-1 receptor agonists are associated with better diabetes control and heart outcomes than metformin in people with type 2 diabetes.
Treatment choice depends on individual factors such as weight, heart and kidney health, side effects and cost, and should be made with a doctor.
Source: Healio















